IP : IXICO plc - Directorate change

IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, today announces that Susan Lowther has resigned from her position as Chief Financial Officer and Company Secretary and stepped down from the Board with effect from 11 December 2018. She will leave the Company today to pursue other business interests. Until a successor is appointed, Conor Wolfson, who has been with the Company for over four years as the Group's Financial Controller, will assume the duties of interim Head of Finance.

Charles Spicer, Non-Executive Chairman of IXICO, said: 'On behalf of the Board, I would like to thank Susan for her many contributions to the Company. She leaves IXICO in a strong financial position to continue executing on its commercially-led growth strategy. We wish her well in her future endeavours. The search for a replacement Chief Financial Officer has been initiated.'

For further information please contact:

IXICO plc	Tel: [phone]
Giulio Cerroni, Chief Executive Officer
Shore Capital (Nomad and Broker)	Tel: [phone]
Edward Mansfield/Anita Ghanekar/Daniel Bush
FTI Consulting Limited (Investor Relations)	Tel: [phone]
Simon Conway/Mo Noonan

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel medical imaging and mobile health digital technologies.

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.